Prediction and validation of enzyme and transporter off-targets for metformin

Metformin, an established first-line treatment for patients with type 2 diabetes, has been associated with gastrointestinal (GI) adverse effects that limit its use. Histamine and serotonin have potent effects on the GI tract. The effects of metformin on histamine and serotonin uptake were evaluated in cell lines overexpressing several amine transporters (OCT1, OCT3 and SERT). Metformin inhibited histamine and serotonin uptake by OCT1, OCT3 and SERT in a dose-dependent manner, with OCT1-mediated amine uptake being most potently inhibited (IC50 = 1.5 mM). A chemoinformatics-based method known as Similarity Ensemble Approach predicted diamine oxidase (DAO) as an additional intestinal target of metformin, with an E-value of 7.4 × 10−5. Inhibition of DAO was experimentally validated using a spectrophotometric assay with putrescine as the substrate. The Ki of metformin for DAO was measured to be 8.6 ± 3.1 mM. In this study, we found that metformin inhibited intestinal amine transporters and DAO at concentrations that may be achieved in the intestine after therapeutic doses. Further studies are warranted to determine the relevance of these interactions to the adverse effects of metformin on the gastrointestinal tract.

[1]  John Kurhanewicz,et al.  OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin , 2014, Proceedings of the National Academy of Sciences.

[2]  Tudor I. Oprea,et al.  Quantifying the Relationships among Drug Classes , 2008, J. Chem. Inf. Model..

[3]  K. Brouwer,et al.  Organic Cation Transporter 1 (OCT1/mOct1) Is Localized in the Apical Membrane of Caco-2 Cell Monolayers and Enterocytes , 2013, Molecular Pharmacology.

[4]  D. Murphy,et al.  Maintenance of Serotonin in the Intestinal Mucosa and Ganglia of Mice that Lack the High-Affinity Serotonin Transporter: Abnormal Intestinal Motility and the Expression of Cation Transporters , 2001, The Journal of Neuroscience.

[5]  R. Arieli,et al.  Hypoxic survival differs between two mole rat species (Spalax ehrenbergi) of humid and arid habitats. , 1991, Comparative biochemistry and physiology. A, Comparative physiology.

[6]  O. Ogawa,et al.  Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. , 2006, Journal of the American Society of Nephrology : JASN.

[7]  M. Gershon.  Review article: roles played by 5‐hydroxytryptamine in the physiology of the bowel , 1999, Alimentary pharmacology & therapeutics.

[8]  K. Giacomini,et al.  Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins , 2011, Molecular Cancer Therapeutics.

[9]  B. Hagenbuch,et al.  Common Drugs Inhibit Human Organic Cation Transporter 1 (OCT1)-Mediated Neurotransmitter Uptake , 2014, Drug Metabolism and Disposition.

[10]  M. Bouchoucha,et al.  Metformin and digestive disorders. , 2011, Diabetes & metabolism.

[11]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[12]  J. Irwin,et al.  Identifying mechanism-of-action targets for drugs and probes , 2012, Proceedings of the National Academy of Sciences.

[13]  N. Novak,et al.  Histamine and histamine intolerance. , 2007, The American journal of clinical nutrition.

[14]  D. Ordóñez,et al.  Inhibition of diamine oxidase from porcine kidney by pentamidine and other aminoguanidine compounds. , 1991, Comparative biochemistry and physiology. B, Comparative biochemistry.

[15]  G. Coruzzi,et al.  An update on histamine H3 receptors and gastrointestinal functions , 1995, Digestive Diseases and Sciences.

[16]  Kazuhiro Watanabe,et al.  Studies on intestinal absorption of sulpiride (2): transepithelial transport of sulpiride across the human intestinal cell line Caco-2. , 2002, Biological & pharmaceutical bulletin.

[17]  Dmitri D. Pervouchine,et al.  The human transcriptome across tissues and individuals , 2015, Science.

[18]  C. Bailey,et al.  Accumulation of metformin by tissues of the normal and diabetic mouse. , 1994, Xenobiotica; the fate of foreign compounds in biological systems.

[19]  G. Tomkin,et al.  The effect of metformin treatment on gastric acid secretion and gastrointestinal hormone levels in normal subjects , 1980, Diabetologia.

[20]  Swati S. More,et al.  Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin , 2010, Pharmacogenetics and genomics.

[21]  W. Bardsley,et al.  Kinetics of the diamine oxidase reaction. , 1973, The Biochemical journal.

[22]  Joanne Wang,et al.  Selective Transport of Monoamine Neurotransmitters by Human Plasma Membrane Monoamine Transporter and Organic Cation Transporter 3 , 2010, Journal of Pharmacology and Experimental Therapeutics.

[23]  J. Hoffman,et al.  Serotonin signalling in the gut—functions, dysfunctions and therapeutic targets , 2013, Nature Reviews Gastroenterology &Hepatology.

[24]  R. Ferner,et al.  Comparative Tolerability Profiles of Oral Antidiabetic Agents , 1994, Drug safety.

[25]  C. Crifó,et al.  Inhibition of diamine oxidase by antihistaminic agents and related drugs , 1979, Agents and Actions.

[26]  A. D. Miller,et al.  Mechanisms of vomiting induced by serotonin-3 receptor agonists in the cat: effect of vagotomy, splanchnicectomy or area postrema lesion. , 1992, The Journal of pharmacology and experimental therapeutics.

[27]  R. Neubert,et al.  Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). , 2005, Biochemical pharmacology.

[28]  H. Bönisch,et al.  Effects of metformin on intestinal 5-hydroxytryptamine (5-HT) release and on 5-HT3 receptors , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.

[29]  B. Viollet,et al.  Cellular and molecular mechanisms of metformin: an overview. , 2012, Clinical science.

[30]  Shuzhong Zhang,et al.  Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. , 2007, The Journal of clinical investigation.

[31]  G. Levy.  RELATIONSHIP BETWEEN RATE OF ELIMINATION OF TUBOCURARINE AND RATE OF DECLINE OF ITS PHARMACOLOGICAL ACTIVITY. , 1964, British journal of anaesthesia.

[32]  G. Baker,et al.  Metabolism of agmatine (clonidine-displacing substance) by diamine oxidase and the possible implications for studies of imidazoline receptors. , 1995, Progress in brain research.

[33]  John P. Overington,et al.  An atlas of genetic influences on human blood metabolites , 2014, Nature Genetics.

[34]  B. D. De Winter,et al.  Histamine H4 receptors in the gastrointestinal tract , 2015, British journal of pharmacology.

[35]  K. Giacomini,et al.  Targeted Disruption of Organic Cation Transporter 3 Attenuates the Pharmacologic Response to Metformin , 2015, Molecular Pharmacology.

[36]  M. Gershon.  Review article: serotonin receptors and transporters — roles in normal and abnormal gastrointestinal motility , 2004, Alimentary pharmacology & therapeutics.

[37]  C. Day,et al.  Effect of metformin on glucose metabolism in the splanchnic bed , 1992, British journal of pharmacology.

[38]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[39]  Yuichi Sugiyama,et al.  Involvement of Organic Cation Transporter 1 in Hepatic and Intestinal Distribution of Metformin , 2002, Journal of Pharmacology and Experimental Therapeutics.

[40]  G. Houen,et al.  New tools for studying old questions: antibodies for human diamine oxidase , 2013, Journal of Neural Transmission.

[41]  P. Dandona,et al.  Diarrhea and Metformin in a Diabetic Clinic , 1983, Diabetes Care.

[42]  D. Thakker,et al.  Four Cation-Selective Transporters Contribute to Apical Uptake and Accumulation of Metformin in Caco-2 Cell Monolayers , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[43]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[44]  G. Coruzzi,et al.  Receptors in the gastrointestinal tract. , 1987, Pharmacological research communications.

[45]  Brian K. Shoichet,et al.  Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4) , 2013, Biochemical pharmacology.

[46]  J Mitchell Guss,et al.  Structure and inhibition of human diamine oxidase. , 2009, Biochemistry.

[47]  G Levy,et al.  Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient , 1980, Clinical pharmacology and therapy.

[48]  C. Palmer,et al.  Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study , 2014, Diabetes.

[49]  K. Giacomini,et al.  Propoxyphene and norpropoxyphene plasma concentrations after oral propoxyphene in cirrhotic patients with and without surgically constructed portacaval shunt , 1980, Clinical pharmacology and therapeutics.

[50]  G Levy,et al.  Kinetics of drug action in disease states. II. Effect of experimental renal dysfunction on phenobarbital concentrations in rats at onset of loss of righting reflect. , 1984, The Journal of pharmacology and experimental therapeutics.

[51]  B. Viollet,et al.  Revisiting the mechanisms of metformin action in the liver. , 2013, Annales d'endocrinologie.

[52]  H. B. Woodruff,et al.  Cefoxitin and cephamycins: microbiological studies. , 1979, Reviews of infectious diseases.

[53]  R. Leurs,et al.  Effects of histamine H1‐, H2‐ and H3‐receptor selective drugs on the mechanical activity of guinea‐pig small and large intestine , 1991, British journal of pharmacology.

[54]  H. Koepsell,et al.  Polyspecific Organic Cation Transporters: Structure, Function, Physiological Roles, and Biopharmaceutical Implications , 2007, Pharmaceutical Research.

[55]  T. Illig,et al.  Association of single nucleotide polymorphisms in the diamine oxidase gene with diamine oxidase serum activities , 2011, Allergy.

[56]  G. Bray,et al.  Long-Term Safety, Tolerability, and Weight Loss Associated With Metformin in the Diabetes Prevention Program Outcomes Study , 2012, Diabetes Care.

[57]  M. Götz,et al.  Histamine‐free diet: treatment of choice for histamine‐induced food intolerance and supporting treatment for chronical headaches , 1993, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[58]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[59]  H. Koepsell,et al.  Reduced Hepatic Uptake and Intestinal Excretion of Organic Cations in Mice with a Targeted Disruption of the Organic Cation Transporter 1 (Oct1 [Slc22a1]) Gene , 2001, Molecular and Cellular Biology.

[60]  A. Schinkel,et al.  Pharmacological and Physiological Functions of the Polyspecific Organic Cation Transporters: OCT1, 2, and 3 (SLC22A1-3) , 2004, Journal of Pharmacology and Experimental Therapeutics.

[61]  M. Jutel,et al.  Histamine and gut mucosal immune regulation , 2014, Allergy.

[62]  J. Tack,et al.  REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY The Serotonin Signaling System: From Basic Understanding To Drug Development for Functional GI Disorders , 2007 .

[63]  Michael J. Keiser,et al.  Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.

[64]  Gary D Stormo,et al.  An Introduction to Sequence Similarity (“Homology”) Searching , 2009, Current protocols in bioinformatics.

[65]  W. Lorenz,et al.  Distribution and properties of human intestinal diamine oxidase and its relevance for the histamine catabolism. , 1983, Biochimica et biophysica acta.

[66]  P. Rangachari,et al.  Probing the "active site" of diamine oxidase: structure-activity relations for histamine potentiation by O-alkylhydroxylamines on colonic epithelium. , 1999, The Journal of pharmacology and experimental therapeutics.

[67]  E. Bodner,et al.  Purification and characterization of diamine oxidase from porcine kidney and intestine. , 1997, Biochimica et Biophysica Acta.

[68]  D. Keppler,et al.  Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver , 2009, Hepatology.

[69]  J. Morrison,et al.  Buffers of constant ionic strength for studying pH-dependent processes. , 1982, Methods in enzymology.

[70]  D. Thakker,et al.  Mechanisms Underlying Saturable Intestinal Absorption of Metformin , 2008, Drug Metabolism and Disposition.

[71]  Andrej Sali,et al.  Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. , 2013, Journal of medicinal chemistry.

[72]  G. Banchelli,et al.  Guanabenz as inhibitor of copper-containing amine oxidases , 1986, Agents and Actions.

[73]  Osamu Ogawa,et al.  Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. , 2007, Biochemical pharmacology.

[74]  S. Masuda,et al.  Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. , 2005, Drug metabolism and pharmacokinetics.

[75]  H. Endou,et al.  Functional analysis of human organic cation transporter OCT3 (SLC22A3) polymorphisms. , 2010, Journal of pharmacological sciences.

[76]  C. Beasley,et al.  Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis. , 2000, Clinical therapeutics.

[77]  M. Danhof,et al.  Kinetics of drug action in disease states. VII. Effect of experimental renal dysfunction on the pharmacodynamics of ethanol in rats. , 1985, The Journal of pharmacology and experimental therapeutics.

[78]  E. Lundberg,et al.  Towards a knowledge-based Human Protein Atlas , 2010, Nature Biotechnology.

[79]  S. Durham,et al.  Basophil expression of diamine oxidase: a novel biomarker of allergen immunotherapy response. , 2015, The Journal of allergy and clinical immunology.

[80]  C. Bailey,et al.  Effects of metformin on bile salt transport by monolayers of human intestinal Caco‐2 cells , 2002, Diabetes, obesity & metabolism.